Pulmonary fibrosis is a condition that causes lung scarring and stiffness. It develops when the alveoli, tiny air sacs that transfer oxygen to the blood, become damaged and inflamed. Body tries to heal the damage with scars, but these scars collapse the alveoli and make the lungs less elastic. Changes in the lungs can also increase the blood pressure in the pulmonary artery.
In Ireland the statistical analysis of pulmonary fibrosis got the result as that of 1076 references, 67 were retrieved and 11 studies included. Studies were of reasonable size, populations were similar, and the overall quality was good. Only two treatments, pirfenidone (odds ratio 0.62, 95% credible interval 0.52, 0.74) and nintedanib (0.41, 95% credible interval 0.34, 0.51) produced a statistically significant slowing in the rate of forced vital capacity decline compared with placebo.